Kornimate/medical-research-clean huggingface dataset:
the effect of local cold application and shotblocker use in subcutaneous injection on injection pain and patient satisfaction

Conditions: Pain; Satisfaction, Patient

Summary: the research was conducted as a single-blind, randomized controlled, experimental study to determine the effect of shotblocker and local cold application on pain and patient satisfaction in subcutaneous heparin injection.

the research was conducted as a single-blind, randomized controlled, experimental study to determine the effect of shotblocker and local cold application on pain and patient satisfaction in subcutaneous heparin injection. the research was conducted with 208 patients hospitalized in the cardiology and internal medicine clinics at izmir atatürk training and research hospital between april 2022 and april 2024. patients were assigned to four groups: shotblocker (n=52), shotblocker placebo (n=52), local cold application (n=52) and control (n=52) groups using the randomization algorithm. a shotblocker was placed on the arm of the patients in the shotblocker group during the injection, and the injection was performed from the part where the opening was located by lightly pressing with the fingertips throughout the injection. during the injection, the back side of the shotblocker was placed on the arm of the patients in the shotblocker placebo group and the injection was performed by gently pressing with the fingertips throughout the injection. local cold application was applied to the arm of the patients in the local cold application group for five minutes using a cold pack, and then the injection was performed. patients in the control group were injected with a routine subcutaneous injection procedure. in all groups, the injection took 30 seconds and was performed by researcher. at the first minute after the injection, the patients were evaluated about the pain they felt during the injection and their satisfaction with the injection by a different reseacher. data were collected by face-to-face interview technique using an informed consent form, individual identification form, visual analog scale and visual patient satisfaction scale. ethics committee permission, institutional permission and written permission from the patients were obtained for the implementation of the research. number, percentage, median, mean, and standard deviation, mann whitney u test, kolmogorov-smirnov test, kruskal wallis h test, bonferroni and chi-square test were used in the analysis of the data.

Eligibility criteria:
inclusion criteria: * enoxaparin sodium 1x1 0.6 ml. sc treatment * over 18 years of age * no vision or hearing problems * no scar tissue, incision, lipodystrophy or infection at the injection site exclusion criteria: * underwent mastectomy * not being voluntering

Keywords: subcutaneous injection shotblocker cold application low molecular weight heparin pain satisfaction
use of real-time continuous glucose monitoring system in patients with type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of this study is to determine whether a real-time continuous glucose monitoring system is able to improve hba1c in patients suffering from type 1 diabetes compared to conventional finger prick glucose measurements. in addition it will investigate whether number of episodes with serious hypoglycemia is changed in those same patients, and whether quality of life (health status and treatment satisfaction) increases.


Eligibility criteria:
inclusion criteria: 1. diabetes mellitus, type 1 \> 3 years. 2. for practical reasons patients should live in trondheim, malvik, melhus or klæbu. 3. level of hba1c (measured by dca 2000) between 7 and 10 % and/or experience blood glucose \< 3 mmol/l (verified by finger-prick measurement) at least once a week and/or at least one episode with serious hypoglycemia the previous half a year.(defined as need of help from others) 4. only patients who use insulin pumps or multi-injection regime (=3 daily injections with short term acting insulin or insulin analogue + at lest one daily injection with nph-insulin or long term acting insulin analogue. exclusion criteria: 1. patients with other diseases such as untreated hypothyroidism, adrenal gland failure, celiac disease, renal failure, unstable coronary heart disease, serious psychiatric disorder, or mental retardation. 2. patients who are not able to learn how to use the continuous glucose monitoring system given a reasonable amount of effort. 3. patients who are not able to do the glucose measurements, insulin dose change and diary notes which the study demands. 4. unsuited for participating from any other cause.

Keywords: real-time glucose monitoring system hba1c quality of life hypoglycemia
juvenile rheumatoid arthritis

Conditions: Juvenile Chronic Arthritis

Summary: the purpose of this study is to determine the safety of anakinra in patients with polyarticular-course juvenile rheumatoid arthritis, a form of rheumatoid arthritis affecting children.


Eligibility criteria:
* male or female age 2-17 yrs inclusive \* minimum weight 10 kg \* diagnosis of chronic arthritis
anti-hep b antibodies at age 12 to 18 months after hep b vaccine at birth and dtap-ipv-hep b-prp-t hexavalent vaccine concomitantly with prevnar® at 2, 4 and 6 months of age

Conditions: Hepatitis B

Summary: primary objective: to describe the persistence of hep b antibodies (ab) at 12 to 18 months of age following a three-dose infant primary series vaccination of either hexaxim®/hexyon®/hexacima® or infanrix® hexa at 2, 4 and 6 months of age following hep b vaccination at birth.

sera from subjects who have participated in study pna19 trial (nct00594347) and for whom parents or legal representatives had given authorization to use the sera taken from their child will be used for this study.

Eligibility criteria:
inclusion criteria: * subjects having received 4 hep b doses in a3l12 (i.e. one dose at birth + three doses during study at 2, 4 \& 6 months of age) * subjects having participated in pna19 * subject's parents having given authorization to use serum collected in pna19 for future research * the initials, birth date, and gender of the subject are consistent between a3l12 and pna19 databases * subjects for whom retention sera are of enough volume to allow a valid determination of the hbsag antibody level. exclusion criteria: * not applicable.

Keywords: hepatitis b hexaxim® hexyon® hexacima® prevnar® dtap-ipv-hb-hib hexavalent vaccine
safety and efficacy of polyheme(r) in hemorrhagic shock following traumatic injuries beginning in the pre-hospital setting

Conditions: Hemorrhagic Shock

Summary: this study is designed to assess the survival benefit of administering polyheme to severely injured trauma patients in hemorrhagic shock beginning in the prehospital setting, where blood is not available, and continuing throughout a 12-hour postinjury hospital setting.


Eligibility criteria:
inclusion criteria: * adult patients following trauma who have sustained blood loss and are in shock exclusion criteria: * patients who have sustained unsurvivable injuries * patients who have severe head injury * pregnant females * patients found in cardiac arrest * patients who object to participation (e.g., religious grounds, wearing exclusion bracelet).
amiodarone usage after ischemic ventricular tachycardia ablation

Conditions: Ischemic Cardiomyopathy; Ventricular Tachycardia; ICD Shock

Summary: ventricular tachycardia ablation in ischemic cardiomyopathy patients is required procedure in cases when anti-arrhythmic drugs failed. the concern is if adjunctive continuation amiodarone after ablation is needed.

ischemic cardiomyopathy patients have implantable cardioverter defibrillators (icd) to prevent arrhythmic deaths. ventricular tachycardia (vt) events with frequent icd interventions in ischemic cardiomyopathy patients is encountered frequently. frequents icd interventions is associated with worse outcomes. anti-arrhythmic drugs ,mostly amiodarone, are given prevent ventricular arrhythmias and icd interventions that may not be curative. ablation of ventricular tachycardia is the suggested treatment when anti-drugs are without effect. after ablation of ventricular arrhythmia the continuation of amiodarone is not well elucidated. in this study we aimed to enroll ischemic cardiomyopathy patients having frequent icd interventions despite medical treatment. vt ablation is performed and patients divided into two groups; group one continues having amiodarone after ablation, group two does not have amiodarone after ablation. both groups will be compared in terms of recurrence and death.

Eligibility criteria:
inclusion criteria: ischemic cardiomyopathy patients applied with frequent icd interventionor electrical storms and having ejection fraction below 50%. frequent icd defined as more than 1 icd intervention within month. electrical storm defined as more than 2 icd intervention within one day. exclusion criteria: patients with cardiomyopathies other than ischemic etiology
assessment of caries diagnosis and caries treatment in dental pbrn japan

Conditions: Dental Caries

Summary: the objective of this study is to examine what methods dental pbrn japan dentists adopt for diagnosis, treatment, and prevention of dental caries.

we conducted a cross-sectional study consisting of a questionnaire survey in japan. we used the same questionnaire as used in the dpbrn study, "assessment of caries diagnosis and caries treatment".

Eligibility criteria:
inclusion criteria: * this study queried dentists working in outpatient dental practices who have affiliated with jdpbrn to investigate research questions and to share experiences and expertise (n = 282). exclusion criteria: * dentist who doesn't perform some measure of restorative dentistry at their practice.

Keywords: dental caries, caries diagnosis, caries treatment, caries risk, practice pattern, clinical epidemiology, dental practice-based research network
egpa and local inflammation within the ear, nose and throat area

Conditions: EGPA - Eosinophilic Granulomatosis With Polyangiitis

Summary: rationale: eosinophilic granulomatosis with polyangiitis (egpa), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (crswnp) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. egpa differs from the other diseases with respect to involvement of other organs. the investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for s. aureus plays an important role in disease expression. the investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. to study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.

see brief summary.

Eligibility criteria:
inclusion criteria: * 18 years of age * able to give informed consent * in crswnp group: availability of bilateral nasal polyps as diagnosed by endoscopy or ct scan * in severe asthma group: clinical diagnosis of asthma with forced expiratory volume at one second(fev1) \ 12% initial or documented positive metacholine challenge (pc20 \< 8 mg/ml) * in egpa group: fulfilling the 2022 acr/eular criteria for egpa (wechsler et al., 2017) * in gpa group: fulfilling the american college of rheumatology (acr)/eular gpa criteria (robson et al., 2022) * in healthy controls: absence of asthma symptoms, no bronchial hyperresponsiveness exclusion criteria: * unable to give informed consent * active smoking \< (less than) 6 months from baseline visit * concomitant use of dupilumab within 6 months of baseline visit * pregnant or breastfeeding woman * in crswnp group: current use of asthma medication, egpa * in healthy controls: chronic use of local anti-inflammatory agents * in healthy controls: use of immunosuppressive medication * in healthy controls: use of antibiotics within the last month (before start study/screening/)
safety and clinical effectiveness of a3 svf in osteoarthritis

Conditions: Osteoarthritis

Summary: to purpose of this study is to determine if treatment with svf (stromal vascular fraction) has an effect on pain and inflammation associated with osteoarthritis.

this is a prospective non-randomized, clinical study of 30 patients to determine safety and treatment potential of a3(adult autologous adipose) svf for the pain and inflammation associated with osteoarthritis. patients will be treated for osteoarthritis due to degeneration or chronic injury. they will be given autologous svf extract derived by the a3 method mixed with activated platelets from a prp(platelet rich plasma) preparation as direct injections to the effected joints. outcomes will be tracked with womac (western ontario and mcmaster universities arthritis index), auscan(australian hand osteoarthritis index) scores, and a general blood panel in order to evaluate systemic effects.

Eligibility criteria:
inclusion criteria: * patients with indication of osteoarthritis. can be from degeneration or chronic injury. * patients range from 15-90 years of age. * female patients not pregnant or lactating. * patients with a history of or current corticosteroid therapy will only be eligible if use is suspended from 1 month prior to cell therapy. * patients must be able to comply with treatment plan, laboratory tests and periodic interviews. * patients with adequate renal function, creatinine ≤ 1.5 mg/dl. * patients with adequate blood coagulation activity, pt(inr) \< 1.5, aptt \<1.5×control. exclusion criteria: * diagnosis of cancer within 5 years prior to screening, except for cutaneous basal cell or squamous cell cancer resolved by excision. * signs and symptoms of clinically significant cardiac disease. * diagnosis of a transient ischemic attack in the 6 months prior to screening, * known allergy to anesthetic or any other components of study. * patients infected with hepatitis b, c or hiv. * patients with body mass index (bmi) \> 39kg/m2 . * any other cardiovascular illness that in the opinion of the investigator would render a patient unsuitable to participate in the study.
home rehabilitation using interactive device versus inpatient rehabilitation in total knee arthroplasty

Conditions: Osteoarthritis, Knee; Arthroplasty; Rehabilitation

Summary: rehabilitation after total knee arthroplasty is very important in terms of range of motion of the knee, muscle power, normal gait, pain control and consequently the patient's satisfaction. convectional rehabilitation methods in assist of therapist required high demand of resources. recently, outpatient clinic or tele-communication tool based rehabilitations were investigated and reported equivalent results. however, those methods also required group or one-to-one facing that restricted availability of the exercise. with development of the motion tracking technology, new device that gives real time feedback with augmented reality images can be used for rehabilitation in home-based setting. this study aims to compare the clinical outcomes after the rehabilitation by interactive home-based device or conventional inpatient setting.

the objective of this work is to compare the pain, stiffness, function and satisfaction between groups at 6 months after the total knee arthroplasty. the investigators hypothesized that the clinical outcomes of rehabilitation by interactive home-based device are not inferior than that by conventional inpatient setting. the study design is a single-blind non-randomized controlled trial. patients takes different rehabilitation method but the outcome assessor is blinded. the clinical outcome is compared at preoperative, postoperative 6weeks, 3months. and clinical outcome consists of range of motion (rom), womac (western ontario and mcmaster university arthritis index ) score, knee society score, time-up-go (tug) test.

Eligibility criteria:
inclusion criteria: * over 19 year old * patients for total knee arthroplasty of one knee * patients who can understand and utilize the device exclusion criteria: * who don't agree with participation of the study * who can not understand and utilize the device * rheumatoid arthritis, other inflammatory arthritis * neuropsychiatric patients
transcranial direct current stimulation for primary progressive aphasia

Conditions: Primary Progressive Aphasia

Summary: in the present sham-controlled study, the investigators examine whether tdcs could be used to enhance language abilities (e.g., picture naming) in individuals with primary progressive aphasia (ppa) primarily characterized by difficulties with speech production.

primary progressive aphasia (ppa) is a neurodegenerative condition characterized by insidious irreversible loss of language abilities. prior studies suggest that transcranial direct current stimulation (tdcs) directed toward language areas of the brain may help to ameliorate symptoms of ppa. in the current study, the investigators are examining whether tdcs could be used to enhance language abilities (e.g., picture naming) in individuals with ppa variants primarily characterized by difficulties with speech production (non-fluent and logopenic). participants are being recruited from the penn frontotemporal dementia center to receive 10 days of both real and sham tdcs (counter-balanced, full-crossover design; participants are naïve to stimulation condition). a battery of language tests are being administered at baseline, immediately post-tdcs (real and sham), and six weeks and twelve weeks following stimulation. real tdcs may improve language performance in some individuals with ppa. specifically, the investigators expect that tdcs will be more effective in people whose baseline performance is worse based on previous research. severity of deficits at baseline may be an important factor in predicting which patients will respond positively to language-targeted tdcs therapies.

Eligibility criteria:
inclusion criteria: * between the ages of 45-80 * native english speaker * diagnosed with primary progressive aphasia * subject understands nature of study and able to give informed consent exclusion criteria: * cognitive impairment of sufficient severity to preclude giving informed consent * history of seizures or unexplained loss of consciousness * previous craniotomy or any breach of the skull * metallic objects in the head or face other than dental braces, fillings or implants * pacemaker or implantable cardioverter-defibrillator * pregnant
effects of folic acid supplementation on arsenic lowering

Conditions: Arsenic Poisoning; Toxic Effect of Arsenic and Its Compounds

Summary: the purpose of this study is to determine whether folic acid supplementation are effective on arsenic lowering in a chronic, low-level arsenic exposed population.

outcome measure: changes of arsenic metabolites at baseline and week 8 methods high-performance liquid chromatography (hplc)

Eligibility criteria:
inclusion criteria: * men or women more than 18 years of age and chronically exposed to arsenic (arsenic concentration of the drinking water \>10ug/l); * population who had no folic acid supplementation in the 2 weeks before the study; * women of childbearing age agreed to use a reliable contraception method during the study; * everyone volunteered to participate and signed informed consent. exclusion criteria: * pregnant or breast-feeding women; * allergic to folic acid; * having clearly defined allergic history; * reported long-term use of folic acid and other vitamins b; * having obvious signs or laboratory abnormalities which could affect the efficacy of folic acid; * unsuitable to participate in the study based on the judgment of the investigators; * not agree to cancel the medications which may affect serum folate concentration during the study period; * subjects who plan to become pregnant during the study or move out of the area within the study period;

Keywords: arsenic induced health problem modifying effects folic acid oxidative damage clinical trial
uninvasive cardiac output monitoring (uscom) in critically ill children: validation and prediction of hemodynamic instability

Conditions: Hemodynamic Instability

Summary: hemodynamically unstable ventilated picu \& pcicu patients, which a decision for commencement in inotropic therapy or fluid bolus has been made, will be recruited. hemodynamic measurements will be carried out before and after therapy have been made, including customary hemodynamic parameters, echocardiography and uscom studies. all parameters will be analyzed for fluid responsiveness or inotropic therapy prediction. trend in uscom parameters will be compared to echocardiography co parameters.


Eligibility criteria:
inclusion criteria: * pediatric critically ill ventilated patients admitted to picu \& pcicu * hemodynamically unstable which a decision for commencement in inotropic therapy or fluid bolus has been made * parental concent exclusion criteria: * cardiac shunt * aortal anomaly \\ repair * tracheostomy * parental refusal to participate

Keywords: pediatric cardiac output fluid responsiveness critically ill hemodynamic monitoring
efficacy and safety of prunus mume extract on improvement of constipation

Conditions: Constipation

Summary: the investigators performed a 8-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of prunus mume extract on improvement of constipation. the investigators measured improvement of constipation parameters , including colonic transit time, number of bowel movement, defecation time, stool type, color and stool amounts per defecation, and monitored their blood pressure.


Eligibility criteria:
inclusion criteria: * males and females 19-40 years old * subject who have functional constipation by rome iiii criteria * subject who have over 36 hour colonic transit time * able to give informed consent exclusion criteria: * subject who have irritable bowel syndrome by rome iiii criteria * allergic or hypersensitive to any of the ingredients in the test products * history of reaction to any of the test products or of gastrointestinal diseases such as crohn's disease or gastrointestinal surgery * history of alcohol or substance abuse * participation in any other clinical trials within past 2 months * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study * pregnant or lactating women etc.